Chong Kun Dang announced on Sept. 13 that it shared the results of the Phase 1 clinical trial on CKD-702, a new anticancer dual antibody biotech drug, at the European Society for Medical Oncology (ESMO) annual conference held in Paris, France from Sept. 9 to 13.Since May 2020, Chong Kun Dang has bee
The U.S. Food and Drug Administration (FDA) will make a decision on awarding marketing approval for Rolontis, the first new biotech drug candidate of Hanmi Pharmaceutical, in September. According to the FDA’s Prescription Drug User Fee Act (PDUFA), Rolontis’ approval deadline is set at Sept. 9.The F
Kolon Life Science has licensed out its osteoarthritis cell gene treatment TG-C, also known as Invossa, to a new biotech company in Singapore in a deal worth up to 720 billion won.The company announced on April 13 that it has signed a 723.4 billion won (US$587.18 million) technology export contract
The Korea Institute of Science and Technology (KIST) announced on March 20 that its research team led by Dr. Jung Young-do has developed a nanomachine that kills a cancer cell by penetrating a cell membrane by means of a molecular movement such as folding and unfolding in a certain cellular environm
The Institute for Basic Science (IBS) and the Ulsan National Institute of Science and Technology (UNIST) announced on Feb. 23 that they have developed Cindela, a side effect-free treatment technique applicable to every cancer without damage to normal cells. Details of the research have been publishe
Hanmi Pharmaceutical announced its R&D plan for this year, including some 30 new drug pipelines currently under development, at the 40th J.P. Morgan Healthcare Conference on Jan. 12 (U.S. local time).The drugmaker also revealed its strategy to develop various new drugs, including a COVID-19 vaccine,
LG Chem introduced its major pipelines, including gout and anticancer drugs, at the JPMorgan Healthcare Conference, which was held online on Jan. 12 (U.S. local time).“We have been greatly strengthening our new drug pipeline through intensive R&D investment and omnidirectional open innovation,” said
HK inno.N, a pharmaceutical subsidiary of Kolmar Korea, announced the latest clinical results of its new drug K-CAB at the JPMorgan Healthcare Conference on Jan. 12 (U.S. local time).The company, previously called CJ HealthCare, disclosed its plan to foster K-CAB as a global blockbuster drug for gas
Hanmi Pharmaceutical announced on Nov. 17 that its CCR4 target immuno-cancer drug "FLX475," which is under joint development with Rapt and MSD of the United States, has reduced the size of a tumor metastasized to a gastric cancer patient by 58 percent.Hanmi Pharmaceutical presented a poster introduc
Chong Kun Dang announced on Nov. 15 that its Indonesian joint venture CKD OTTO has signed an export contract worth US$32 million with Algeria's largest state-run pharmaceutical company Saidal and shipped the first batch.Under the contract, CKD-OTTO will export anticancer injections produced in I
HLB announced on Nov. 8 that its oral cancer drug candidate "Rivoceranib" has been designated as an orphan drug for liver cancer treatment by the U.S. Food and Drug Administration (FDA) on Nov. 4.The FDA operates the Orphan Drug Designation (ODD) program to support the development of orphan drugs.Or
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Yuhan plans to apply for breakthrough therapy approval for Lazertinib within the year, with the results of its CHRYSALIS-2 clinical trials and entry in the US expected to materialize in 2022. Noting
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association announced on Sept. 5 that 193 out of the 299 South Korean companies in the industry are working on 1,477 new drug pipelines. For reference, 100 companies were working on 573 new drugs according to the association’s 2018 survey.The 1,4
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. SK Biopharm reported consolidated 2Q21 sales of W23.97bn and operating losses of W65.08bn, missing consensus. SG&A expense increase resulted in OP decline, but US sales of Xcopri grew solidly to W18.
The Ministry of Health and Welfare and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association launched the Next-generation mRNA Vaccine Platform Technology Consortium on June 29. The consortium led by Hanmi Pharmaceutical, ST Pharm and GC Pharma and supported by the Korea Innovative Medic
U.S. pharmaceutical ingredient manufacturer AMPAC Fine Chemicals is planning to expand its facilities in the United States by investing up to US$25 million. The idea is to enhance its competitiveness in the field of contract development and manufacturing by strengthening its R&D functions and increa
Hanmi Pharmaceutical has failed to receive approval for its anti-cancer substance "Oraxol" from the U.S. Food and Drug Administration (FDA).Hanmi Pharmaceutical licensed out Oraxol technology to Athenex, a U.S. pharmaceutical company, in 2011. Athenex said on March 1 (local time) that it has receive
Boryung Pharmaceutical has signed a contract with SN BioScience for exclusive sale in Korea of the world's first nano-micelle anticancer drug SN-101 (component name: Nanocomposite SN-38).Through this contract, Boryung Pharmaceutical will hold exclusive sales rights in Korea for 10 years after th
The Federation of Korean Industries (FKI) recently analyzed foreign direct investment (FDI) for the period starting in 2011 and announced that the reported FDI continued to increase until 2018, fell 13.3 percent to US$23.33 billion in 2019 and fell 4.7 percent year on year to US$12.85 billion in the
Korea Exchange decided on Nov. 4 to delist Kolon TissueGene. Previously, it turned out that its Invossa-K, the world’s first gene therapy product for osteoarthritis patients, contains renal cells instead of chondrocytes and the Ministry of Food and Drug Safety canceled its approval in May last year